Long-Term Safety and Durability of IPS101A in Parkinson's Disease
Official title: A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product in the IPS101A-10 Phase I Clinical Trial
Run by Innopeutics Corporation · NCT07629115 · Data updated 2026-11-12
This long-term follow-up checks if IPS101A continues to be safe and whether its benefits last for people with Parkinson's who previously received the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 6 (estimated) |
| Sponsor | Innopeutics Corporation Industry-sponsored |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | May 29, 2026 |
| Main results expected | July 30, 2031 |
| Study ends | October 30, 2031 |
| Registry record updated | July 1, 2026 |
| Trial ID | NCT07629115 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with Parkinson's disease who previously participated in the IPS101A-10 trial and provided written consent for long-term follow-up.
✕Probably not a fit
Individuals who de-enroll or are unable to complete follow-up visits may not experience additional monitored benefits from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational follow-up study monitors participants who received the IPS101A gene therapy in a prior trial to assess long-term safety outcomes. It also explores how durable any treatment effects are over time in this patient group. Enrollment is limited to individuals from the IPS101A-10 trial who consented to extended follow-up, with ongoing assessments aligned to standard follow-up schedules. The study is sponsored by Innopeutics Corporation and conducted at Severance Hospital in Seoul. No additional interventions are specified for this follow-up beyond continued observation and data collection.
Why it matters
Potential benefit: If IPS101A remains safe and benefits persist, patients may have sustained symptom stability or improvement over the long term.
How similar studies have gone: Other long-term follow-up studies of gene therapies in neurological diseases have reported safety data and durability of effects, but this exact IPS101A follow-up is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A. * Subjects and/or their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements. Exclusion Criteria * Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons. * Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.
Where it's running
-
Severance Hospital
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: ChoLong Park
- Email: clpark@innopeutics.com
- Phone: +82-2-3499-4266
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
IPS101A AAV gene therapy for advanced Parkinson's disease
This Phase 1 test will see if IPS101A, an AAV gene therapy, is safe and helps people aged 50–80 with advanced Parkinson's (Hoehn & Yahr 4–5) whose symptoms are not controlled by standard treatments.
-
Detecting Parkinson's-related alpha-synuclein in colon tissue taken during routine colonoscopy
This will see if small extra colon tissue samples taken during a routine colonoscopy can find phosphorylated alpha-synuclein in people with Parkinson's disease or REM sleep behavior disorder.
-
Understanding serotonin release in Parkinson's disease
This study is trying to find a way to see changes in the brain of people with Parkinson's disease to help develop new treatments that could slow down the symptoms.
-
Investigating biomarkers for Parkinson's disease using advanced imaging techniques
This study is trying to find a marker for Parkinson's disease by using advanced brain scans to see how the disease affects brain chemistry and structure over time.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.